Hydrogen Flush After Cold Storage as a New End-Ischemic Ex Vivo Treatment for Liver Grafts Against Ischemia/Reperfusion Injury.
Tamaki I, Hata K, Okamura Y, Nigmet Y, Hirao H, Kubota T, Inamoto O, Kusakabe J, Goto T, Tajima T, Yoshikawa J, Tanaka H, Tsuruyama T, Tolba RH, Uemoto S · Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2018
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Hydrogen Flush After Cold Storage as a New End-Ischemic Ex Vivo Treatment for Liver Grafts Against Ischemia/Reperfusion Injury.” is organized in H2HUBB under the research focus molecular hydrogen fatty liver study 2018. The publication is cited as Tamaki I, Hata K, Okamura Y, Nigmet Y, Hirao H, Kubota T, Inamoto O, Kusakabe J, Goto T, Tajima T, Yoshikawa J, Tanaka H, Tsuruyama T, Tolba RH, Uemoto S, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2018. This in vitro or cellular study examined Hydrogen Flush After Cold Storage as a New End-Ischemic Ex Vivo Treatment for Liver Grafts Against Ischemia/Reperfusion Injury. The abstract describes Cell culture / in vitro model. This is an automated editorial draft based on the abstract and requires source review before publication.
Molecular hydrogen fatty liver study 2018 overview
Functional integrity and morphological damages were then evaluated by 2-hour oxygenated reperfusion at 37°C. Laboratory and cellular research can clarify mechanisms, but it does not establish clinical benefit or reproduce the complexity of a living human system.
Study design and hydrogen intervention
Publication type: In vitro or cellular study. Evidence type: Laboratory or cellular evidence. Research model or population: Cell culture / in vitro model. Blinding: Unknown. Control status: Unknown.
Delivery method: Other or not reported.
Reported findings and scientific interpretation
For this molecular hydrogen fatty liver study 2018, the study record reports the following: No detailed finding statement was available for this record. Readers should consult the original publication before drawing conclusions.
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: Laboratory findings may not translate directly to living organisms or clinical outcomes.
Safety: Given its safety, simplicity, and cost-effectiveness, end-ischemic HyFACS may be a novel pretransplant conditioning for cold-stored donor organs.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.